Promoting research partnerships 

to improve veterans’ health

NAVREF News Center

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 10 Jan 2019 3:04 PM | Hawk Tran (Administrator)

    The NIH has a funding opportunity available that might be beneficial for your NPC! There are now open RFAs related to the HEAL (Helping to End Addiction Long-termSM) ) initiative. Learn more about the initiative and opportunities with the link below:

    https://www.aamc.org/download/493374/data/nihheal.pdf

  • 8 Jan 2019 2:35 PM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $130 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in January 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications submitted to the FY19 BCRP must address one or more of the following overarching challenges:

    • Prevent breast cancer (primary prevention)
    • Identify determinants of breast cancer initiation, risk, or susceptibility
    • Distinguish deadly from non-deadly breast cancers
    • Conquer the problems of overdiagnosis and overtreatment
    • Identify what drives breast cancer growth; determine how to stop it
    • Identify why some breast cancers become metastatic
    • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
    • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
    • Eliminate the mortality associated with metastatic breast cancer

    https://cdmrp.army.mil/pubs/press/2019/19bcrppreann

    Breakthrough Award

    • Investigators at all academic levels (or equivalent)
    • Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship
    • Award are encouraged to apply under Funding Levels 1 and 2
    • Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
    • Potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.
    • Partnering PI Option allows two Principal Investigators (PIs), termed Initiating and Partnering PIs, to collaborate on a single application.
    • Different funding levels, based on the scope of research, are available.  It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

    The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

    • Funding Level 1:  Innovative, high-risk/high-reward research that is in the earliest stages of idea development.  In order to foster research with clearly defined potential to yield new avenues of investigation, preliminary data are not required. Proof-of-concept is the anticipated outcome.
    • Funding Level 2:  Preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.
    • Funding Level 2 – Population Science and Prevention Studies: With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance. Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.
    • Funding Level 3:  Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. If the proposed research would ultimately require US Food and Drug Administration (FDA) involvement, applications must demonstrate availability of and access to clinical reagents (e.g. therapeutic molecules) and subject population(s). Applications must state a realistic timeline for near-term clinical investigation. Small-scale clinical trials (e.g. first in human; Phase I/Ib) may be appropriate.
    • Funding Level 4:  Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer.  Human clinical trials are required. PIs are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical project successfully. Where relevant, applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or critical reagents. For proposed research that will require FDA involvement, project readiness requirements at the time of application submission include: proof of availability of and access to clinical reagents (e.g. therapeutics) that meet regulatory compliance guidelines; proof of availability of and access to appropriate subject population(s); validated projections for patient recruitment; and submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the FDA, if applicable.

    Funding Levels 1 and 2:

    ·       Submission of a Letter of Intent is required prior to full application submission.

    ·       Each PI may submit only one application as a PI or Initiating PI for each funding level.  There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

    ·       Additional funds are available for applications submitted under the Partnering PI Option.

    ·       Clinical trials are not allowed.

    Funding Levels 3 and 4:

    ·       Submission of a preproposal is required; application submission is by invitation only.

    ·       Each PI may submit only one application as a PI or Initiating PI for each funding level.  There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

    ·       Additional funds are available for Funding Level 3 applications submitted under the Partnering PI Option.

    ·       PIs must include two or more breast cancer advocates on their research team.

    Clinical trials are allowed (Funding Level 3) or required (Funding Level 4).

    Funding Level 1:

    Maximum funding of $450,000 for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 1 – Partnering PI Option:

    Maximum funding of $750,000 for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 2:

    Maximum funding of $1 million (M) for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 2 – Partnering PI Option:

    Maximum funding of $1.5M for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 2 – Population Science and Prevention Studies

    Maximum funding of $1.5M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 2 – Population Science and Prevention Studies – Partnering PI Option

    Maximum funding of $2M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 3:

    Maximum funding of $3M in direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 3 – Partnering PI Option:

    Maximum funding of $4M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 4 and Funding Level 4 – Partnering PI Option:

    Maximum funding of $10M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Breakthrough Fellowship Award

    As of the application submission deadline, all eligible PIs must have:

    ·       Successfully completed the requirements for a doctoral or medical degree, and

    ·       Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

    ·       A total of less than 4 years’ experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

    Mentor

    ·       Must have breast cancer research experience, including current funding and recent publications

    ·       Supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research.

    ·       Proposed research must have high potential to lead to or make breakthroughs in breast cancer and show evidence of rigorous experimental design, sufficient experimental details, appropriate controls, pitfalls and alternatives, and a statistical plan.

    ·       Individualized researcher development plan and mentorship should prepare the PI for an independent career at the forefront of breast cancer research or patient care.

    ·       The PI is not required to have previous experience in breast cancer research.

    ·       Submission of a Letter of Intent is required prior to full application submission.

    ·       Maximum funding of $300,000 for direct costs (plus indirect costs)

    ·       Maximum period of performance is 3 years

    Era of Hope Scholar Award

    • Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

    ·       Supports exceptionally talented, early-career scientists who have demonstrated that they are the “best and brightest” in their fields through extraordinary creativity, vision, innovation, and productivity.

    ·       PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

    ·       PIs must demonstrate experience in forming effective partnerships and collaborations and exhibit strong potential for future leadership in breast cancer.

    ·       PIs are required to include two or more breast cancer advocates on their research team.

    • Submission of a Letter of Intent is required prior to full application submission.

    ·       Maximum funding of $3M for direct costs (plus indirect costs)

    • Maximum period of performance is 4 years

    Innovator Award

    • Associate Professor or above (or equivalent).

    ·       Supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field.

    ·       Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.

    ·       PIs must include two or more breast cancer advocates on their research team.

    Submission of a preproposal is required; application submission is by invitation only.

    ·       Maximum funding of $5M for direct costs (plus indirect costs).

    • Maximum period of performance is 4 years

    Distinguished Investigator Award

    • Assistant Professor or above (or equivalent) and more than 6 years beyond the PI’s last training position as of the application submission deadline

    ·       Seeks new paradigms in breast cancer research by supporting investigators who are established and recognized leaders with a renowned reputation as a researcher who has made groundbreaking contributions to advancing their field and who propose a fundamental shift from their track record of research.

    ·       Does not support continuation of or incremental changes from the PI’s published line of research. A shift from a different malignancy to breast cancer may not constitute a fundamental shift.

    ·       If the PI is not an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a conceptual shift in his/her research and must include at least one collaborator with breast cancer expertise.

    ·       PIs must include two or more breast cancer advocates on their research team.

    ·       High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.

    ·       Submission of a preproposal is required; application submission is by invitation only.

    ·       Maximum funding of $3M for direct costs (plus indirect costs)

    ·       Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 20 Dec 2018 12:24 PM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Ovarian Cancer Research Program (OCRP) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in January 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    https://cdmrp.army.mil/pubs/press/2019/19ocrppreann

    Clinical Development Award

    Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    ·        Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

    ·        Near-term impact is expected.

    ·        Preclinical studies in animals are not allowed.

    ·        Small-scale clinical trials (Phase 0, Phase 1, Pilot) studies enriching a clinical trial and projects related to or associated with ongoing or completed clinical trials are allowed.

    ·        Preliminary data are required.

    ·        Optional Nested Early-Career Investigator (ECI):  Applications proposing clinical trials and having an ECI that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.

    ·        Pre-application is required; application is by invitation only.

    ·        Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·        With the ECI option, the maximum funding is $800,000 for direct costs (plus indirect costs).

    ·        Maximum period of performance is 3 years.

    Investigator-Initiated Research Award

    Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    ·        Supports meritorious basic and clinically oriented research in ovarian cancer.

    ·        Impact is an important review criterion.

    ·        Preliminary data are required.

    ·        Clinical trials are not allowed. 

    ·        Pre-application is required; application is by invitation only.

    ·      Maximum funding of $450,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

    Ovarian Cancer Academy Award – Early-Career Investigator

    Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline.  A letter attesting to eligibility is required.

    ·      Supports the addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.

    ·      ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

    ·      A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.

    ·      A Designated Mentor may only mentor one ECI candidate.

    ·      The Designated Mentor is not required to be at the same institution as the ECI.

    ·      Preliminary data are required.

    ·      Clinical trials are allowed.

    ·      Maximum funding of $725,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is years, with a 5th-year option.

    ·      Pre-application is required; application is by invitation only.

    Ovarian Cancer Academy Dean Award

    Dean must be an established ovarian cancer researcher.

    ·      Embedded Assistant Dean must be an independent ovarian cancer research at a different institution from the Dean.

    ·      Supports visionary individuals who are established ovarian cancer researchers with a strong record of mentoring and commitment to leadership.

    ·      Academy Dean, with Assistant Dean, will oversee an interactive academy of ECIs and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the ECIs.

    ·      Pre-application is required; application is by invitation only.

    ·      Maximum funding of $1,750,000 in direct costs (plus indirect costs).

    ·      The Dean and Assistant Dean are expected to be partners in leading the Academy, and the direct cost funding should be divided accordingly.

    ·      Period of performance is years, with a 5th-year option.

    Pilot Award

    Investigators at or above the postdoctoral level (or equivalent).

    ·      Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.

    ·      Innovation and Impact are important review criteria.

    ·      Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.

    ·      Clinical trials are not allowed.

    ·      Pre-application is required and blinded; application submission is by invitation only.

    ·      Maximum funding of $250,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org.  For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 21 Nov 2018 8:49 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriations Act provides $10 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP)to support innovative and high-impact research into preclinical development of therapeutics for Amyotrophic Lateral Sclerosis.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation.  The managing agent for the Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The mission of the ALSRP is to fund innovative preclinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

    https://cdmrp.army.mil/funding/alsrp

    The following mechanisms have been released:

    Therapeutic Development Award – Preproposal due by 3/22/19

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only
    • Supports post-discovery, preclinical development of therapeutics for ALS
    • Preliminary data, including identity and purity of an identified bioactive compound(s), are required
    • Therapeutically Relevant Marker Option available
    • Collaboration with industry is encouraged
    • Clinical trials are not allowed
    • Maximum funding of $1.0 million for direct costs (plus indirect costs); $1.25 million for direct costs (plus indirect costs) for applications including the Therapeutic Relevant Marker Option
    • Maximum period of performance is years

    Therapeutic Idea Award – Preproposal due by 3/22/19

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only
    • Supports screening methods or new ideas aimed at ALS drug or treatment discovery still in the early stages of development
    • Preliminary data are not required
    • Not intended to support projects focusing on the pathophysiology of ALS
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@Ebrap.org

    Book mark the CDMRP website:

    cdmrp.army.mil

    Follow CDMRP on Twitter at:

    twitter.com/CDMRP

    View CDMRP research results on YouTube:

    www.youtube.com/user/CDMRP

    Like us on FaceBook:

    www.facebook.com/TheCDMRP


  • 6 Nov 2018 1:28 PM | Hawk Tran (Administrator)

    The FY19 Defense Appropriations Act provides $350 million (M) to the Department of Defense Peer Reviewed Medical Research Program (PRMRP) to support or medical research projects of clear scientific merit and direct relevance to military health.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The PRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRMRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in November 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    The vision and mission of the PRMRP is improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.
    Congressionally Directed Topic Areas:  All applications submitted to the PRMRP must address at least one of the FY19 PRMRP Congressionally directed topic areas.  The FY19 PRMRP Topic Areas are as follows:
     
    .       Acute Lung Injury
    .       Antimicrobial Resistance
    .       Arthritis
    .       Burn Pit Exposure
    .       Cardiomyopathy
    .       Cerebellar Ataxia
    .       Chronic Migraine and Post-Traumatic Headache
    .       Congenital Heart Disease
    .       Constrictive Bronchiolitis
    .       Diabetes
    .       Dystonia
    .       Eating Disorders
    .       Emerging Infectious Diseases
    .       Epidermolysis Bullosa
    .       Focal Segmental Glomerulosclerosis
    .       Frontotemporal Degeneration
    .       Guillain-Barré Syndrome
    .       Hemorrhage Control
    .       Hepatitis B
    .       Hereditary Angioedema
    .       Hydrocephalus
    .       Immunomonitoring of Intestinal Transplants
    .       Inflammatory Bowel Diseases
    .       Interstitial Cystitis
    .       Lung Injury
    .       Metals Toxicology
    .       Mitochondrial Disease
    .       Musculoskeletal Disorders
    .       Myotonic Dystrophy
    .       Nanomaterials for Bone Regeneration
    .       Nutrition Optimization
    .       Pancreatitis
    .       Pathogen-Inactivated Blood Products
    .       Polycystic Kidney Disease
    .       Post-Traumatic Osteoarthritis
    .       Pressure Ulcers
    .       Pulmonary Fibrosis
    .       Resilience Training
    .       Respiratory Health
    .       Rett Syndrome
    .       Rheumatoid Arthritis
    .       Scleroderma
    .       Sleep Disorders
    .       Spinal Muscular Atrophy
    .       Tinnitus
    .       Tissue Regeneration
    .       Tuberculosis
    .       Vascular Malformations
    .       Women's Heart Disease
     

    The following mechanisms are planned for release:
           
    http://cdmrp.army.mil/pubs/press/2019/19prmrppreann

    Clinical Trial Award
    .       Assistant Professor level or above (or equivalent)
    .       Preproposal submission is required; application submission is by invitation only.
    .       Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic         area(s) of interest.
    .       Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
    .       Investigational New Drug or Investigational Device Exemption applications, if needed, should be approved by the Food and Drug Administration before      the PRMRP application submission deadline.
    .       Funding limit not defined; requested funding must be appropriate for the scope of work proposed
    .       Maximum period of performance is 4 years

    Discovery Award
    .       Postdoctoral fellow or clinical fellow (or equivalent) and above
    .       Supports the exploration of a highly innovative new concept or untested theory.
    .       Not intended to support the logical progression of an already established line of questioning.
    .       Clinical trials will not be funded.
    .       Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
    .       Maximum of $200,000 for direct costs (plus indirect costs)
    .       Maximum period of performance is 2 year

    Focused Program Award
    .       Full Professor level or above (or equivalent)
    .       Preproposal submission is required; application submission is by invitation only.
    .       Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
    .       Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
    .       Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
    .       Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
    .       Maximum of $7.2 million for direct costs (plus indirect costs)
    .       Maximum period of performance is 4 years

    Investigator-Initiated Research Award
    .       Assistant Professor level or above (or equivalent)
    .       Preproposal submission is required; application submission is by invitation only.
    .       Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
    .       Partnering PI Option available.
    .       Clinical trials will not be funded.
    .       Maximum of $1.2 million for direct costs (plus indirect costs)
    .       Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option
    .       Maximum period of performance is 3 years

    Technology/ Therapeutic Development Award
    .       Assistant Professor level or above (or equivalent)
    .       Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life.
    .       Product-oriented (e.g., device, drug, clinical guidelines).  The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or       biologics) or device, or a knowledge-based product.
    .       Clinical trials will not be funded.
    .       Preproposal submission is required; application submission is by invitation only.
    .       Maximum of $3.0 million for direct costs (plus indirect costs)
    .       Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government's single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org.  For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:
    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
    Book mark the CDMRP website:
    cdmrp.army.mil

    Follow CDMRP on Twitter at:
    twitter.com/CDMRP

    View CDMRP research results on YouTube:
    www.youtube.com/user/CDMRP

    Like us on FaceBook:
    www.facebook.com/TheCDMRP


  • 5 Nov 2018 3:34 PM | Hawk Tran (Administrator)

    The National Institutes of Health (NIH) recently released a revised NIH Grants Policy Statement (NIHGPS, rev. October 2018).  The NIHGPS makes available in a single document the policy requirements that serve as the terms and conditions of NIH grant awards. The October 2018 revision is applicable to all NIH grants and cooperative agreements with budget periods beginning on or after October 1, 2018. Previous versions of the NIHGPS remain applicable as a standard term and condition for all NIH grants and cooperative agreements with budget periods that began prior to October 1, 2018.

     

    More information:


  • 30 Oct 2018 11:42 AM | Hawk Tran (Administrator)

    Two NPCs have successfully requested and received approval to increase their micro-purchase threshold from $10,000 to $25,000. The process is straight-forward and can be handled through email request and response.  As detailed in OMB Memo M-18-18, dated June 20, 2018,

    “to receive a higher threshold, the institution must either have "clean single audit findings" (i.e., in accordance with 2 C.F.R. § 200.520 - Criteria for a low-risk auditee), have an acceptable internal institutional risk assessment, or the higher threshold must be consistent with State law for public institutions.”

    Requests for approval should be submitted to the institution's cognizant Federal agency for indirect cost rates—please reach out to NAVREF for specific contact information and please check out the documents below to help you successfully increase your micro-purchase threshold. 


    SAMPLE DOCUMENTS PROVIDED BY THE SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH:

    SIBCR Procurement Policy

    SIBCR Vendor Justification Form

    SIBCR Purchase Order Form

    FY19 Purchase Order Instructions

    DHHS Micro-Threshold Approval Email Message



  • 17 Oct 2018 10:56 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriations Act provides $10 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) to support innovative and high-impact research into preclinical development of therapeutics for Amyotrophic Lateral Sclerosis.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The ALSRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in November 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    The mission of the ALSRP is to fund innovative preclinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

    http://cdmrp.army.mil/pubs/press/2019/19alsrppreann

    The following mechanisms are planned for release:

    Therapeutic Development Award

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only
    • Supports post-discovery, preclinical advancement of therapeutics for ALS
    • Preliminary data, including identity and purity of an identified bioactive compound(s), are required
    • Clinical trials are not allowed
    • Types of efforts that will be supported include:
      • Confirmation of candidate therapeutics obtained from screening or by other means
      • Validation of early pilot studies in multiple model systems and/or replicating preliminary data with more time points or additional doses
      • Optimization of potency and pharmacology, studies of formulation, stability, and production methods based on Good Manufacturing Practices
      • Investigational New Drug-enabling studies
      • Optional Therapeutic Relevance Option: Applications proposing development of markers to improve the drug development process in parallel with the main therapeutic advancement effort and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding
    • Maximum funding of $1,000,000 for direct costs (plus indirect costs)
    • If applying for the Therapeutic Relevance Option, the maximum funding is $1,250,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years

    Therapeutic Idea Award

    • Independent investigators at all academic levels
    • Pre-application is required; full application submission is by invitation only
    • Supports new ideas aimed at drug or treatment discovery that are still in the early stages of development
    • Preliminary data are not required
    • Types of efforts that will be supported include:
      • Exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality
      • Development, modification, and use of high-throughput screens and novel model systems to define or assess lead compounds
    • Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this award mechanism
    • Maximum funding of $500,000 for direct costs (plus indirect costs)
    • Maximum period of performance is years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

    Book mark the CDMRP website:

    cdmrp.army.mil

    Follow CDMRP on Twitter at:

    twitter.com/CDMRP

    View CDMRP research results on YouTube:

    www.youtube.com/user/CDMRP

    Like us on FaceBook:

    www.facebook.com/TheCDMRP


  • 16 Oct 2018 9:02 AM | Hawk Tran (Administrator)

    FY19 Topic Areas for the Peer Reviewed Cancer Research Program

    *            Bladder cancer

    *            Blood Cancers

    *            Brain Cancer

    *            Cancer in children, adolescents, and young adults1

    *            Colorectal cancer

    *            Immunotherapy2

    *            Listeria vaccine for cancer

    *            Liver cancer

    *            Lymphoma

    *            Mesothelioma

    *            Neuroblastoma

    *            Pancreatic cancer

    *            Pediatric brain tumors

    *            Rare cancers3

    *            Stomach cancer

    Funding for research into breast, kidney, lung, melanoma, ovarian, and prostate cancers is not allowed under the FY19 Peer Reviewed Cancer Research Program.

    1The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between the ages of 15-39 years. Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s). Research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years) and/or young adults (ages 25-39 years).

    2As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms). Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer. Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

    3Rare cancer is defined by the National Cancer Institute as a cancer that occurs in fewer than 15 out of 100,000 people each year (http://www.cancer.gov/publications/dictionaries/cancer-terms/def/791790). Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

    Jennie Mettert-Young

    Public Affairs

    For the USAMRMC, CDMRP

    Ripple Effect

    Fort Detrick, MD 21702-5024

    Usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

    Book mark the CDMRP website:

    cdmrp.army.mil

    Follow CDMRP on Twitter at:

    twitter.com/CDMRP

    View CDMRP research results on YouTube:

    www.youtube.com/user/CDMRP

    Like us on FaceBook:

    www.facebook.com/TheCDMRP


  • 12 Oct 2018 11:19 AM | Hawk Tran (Administrator)

    The Fiscal Year 2019 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP):

    http://cdmrp.army.mil/pubs/press/2019/funding_press_release19

    • Alcohol and Substance Abuse Research Program - $4.0 million
    • Amyotrophic Lateral Sclerosis Research Program - $10.0 million
    • Autism Research Program - $7.5 million
    • Bone Marrow Failure Research Program - $3.0 million
    • Breast Cancer Research Program - $130.0 million
    • Duchenne Muscular Dystrophy Research Program - $3.2 million
    • Epilepsy Research Program - $7.5 million
    • Gulf War Illness Research Program - $22.0 million
    • Hearing Restoration Research Program - $10.0 million
    • Kidney Cancer Research Program - $20.0 million
    • Joint Warfighter Medical Research Program - $50.0 million
    • Lung Cancer Research Program - $14.0 million
    • Lupus Research Program - $5.0 million
    • *Melanoma Research Program - $10.0 million (*new for FY19)
    • Military Burn Research Program - $8.0 million
    • Multiple Sclerosis Research Program - $6.0 million
    • Neurofibromatosis Research Program - $15.0 million
    • Orthotics and Prosthetics Outcomes Research Program- $10.0 million
    • Ovarian Cancer Research Program - $20.0 million
    • Parkinson's Research Program - $16.0 million
    • Peer Reviewed Alzheimer's Research Program - $15.0 million
    • Peer Reviewed Cancer Research Program (15 Topics) - $90.0 million
    • Peer Reviewed Medical Research Program (49 Topics) - $350.0 million
    • Peer Reviewed Orthopaedic Research Program - $30.0 million
    • Prostate Cancer Research Program - $100.0 million
    • Reconstructive Transplant Research Program - $12.0 million
    • Spinal Cord Injury Research Program - $30.0 million
    • Tick-Borne Disease Research Program - $5.0 million
    • Tuberous Sclerosis Complex Research Program - $6.0 million
    • Vision Research Program - $20.0 million

    Comprehensive Program Announcements will be released during 2019. The Program Announcements will include detailed descriptions of funding mechanisms, evaluation criteria, submission requirements, and deadlines. Each Program Announcement may be downloaded from the Grants.gov website http://www.grants.gov, or the CDMRP website http://cdmrp.army.mil upon its release.

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org.

    For more information about the CDMRP, our research programs, previous awardees, as well as research highlights and videos, please visit the website at http://cdmrp.army.mil.

    Point of Contact:

    CDMRP Public Affairs
    301-619-7783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

    Book mark the CDMRP website:

    cdmrp.army.mil

     

    Follow CDMRP on Twitter at:

    twitter.com/CDMRP

     

    View CDMRP research results on YouTube:

    www.youtube.com/user/CDMRP

     

    Like us on FaceBook:

    www.facebook.com/TheCDMRP


<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software